Papa Medical Files S-1/A Amendment 3 for Public Offering

TL;DR

**Papa Medical is pushing ahead with its IPO, but the 'Cigarettes' SIC code is a red flag demanding immediate clarification for any serious investor.**

AI Summary

Papa Medical Inc. filed an S-1/A on August 7, 2025, as Amendment No. 3 to its S-1 Registration Statement, indicating a proposed sale to the public as soon as practicable. The company, incorporated in Delaware with a primary SIC Code of 2111 (Cigarettes), is headquartered at 202 North California Ave, City of Industry, CA 91744. While the filing details the registration process and legal counsel, specific financial figures for revenue or net income are not provided in this amendment. The S-1/A primarily updates administrative and legal information, including the appointment of Hua Yao as Chief Financial Officer and agent for service. Key business changes or strategic outlooks are not explicitly detailed in this amendment, which focuses on the procedural aspects of the public offering. The company's fiscal year ends on December 31. The filing does not contain information regarding specific risks or a strategic outlook beyond the intent to go public.

Why It Matters

This S-1/A filing signals Papa Medical Inc.'s continued progress towards a public offering, which could introduce a new competitor in the medical device or related sector, despite its unusual SIC code of 'Cigarettes'. For investors, it represents a potential new investment opportunity, though due diligence on its actual business model is crucial given the SIC discrepancy. Employees may see increased scrutiny and potential for stock-based compensation, while customers could benefit from new product development if the IPO funds growth. The broader market will watch to see how Papa Medical positions itself against established players in its true industry, which is not clearly defined by the provided SIC code.

Risk Assessment

Risk Level: high — The primary risk stems from Papa Medical Inc.'s listed Standard Industrial Classification (SIC) Code 2111, which is 'Cigarettes'. This is highly unusual and potentially misleading for a company named 'Papa Medical Inc.', suggesting a significant mismatch between its stated name and its official industry classification. This discrepancy could indicate a misclassification, a diversified business model not immediately apparent, or a lack of transparency, all of which elevate investor risk.

Analyst Insight

Investors should immediately investigate the discrepancy between Papa Medical Inc.'s name and its SIC Code 2111 ('Cigarettes') before considering any investment. Demand clarity on the company's actual business operations and market position, as this filing provides insufficient information to assess its true industry or financial health.

Key Numbers

• 0002024283 — Central Index Key (CIK) (Unique identifier for Papa Medical Inc. with the SEC)
• 2111 — Standard Industrial Classification (SIC) Code (Primary SIC code listed as 'Cigarettes', which is highly unusual for a 'Medical' company)
• 333-283405 — Registration No. (SEC file number for the S-1 registration statement)
• 99-0986423 — I.R.S. Employer Identification Number (EIN) (Tax identification number for Papa Medical Inc.)
• (626) 855-0800 — Business Phone Number (Main contact number for Papa Medical Inc.)
• August 7, 2025 — Filing Date (Date the S-1/A Amendment No. 3 was filed with the SEC)
• December 31 — Fiscal Year End (The date Papa Medical Inc.'s fiscal year concludes)

Key Players & Entities

• Papa Medical Inc. (company) — Registrant for S-1/A filing
• Hua Yao (person) — Chief Financial Officer and agent for service
• Loeb & Loeb LLP (company) — Legal counsel for the Registrant
• Winston & Strawn LLP (company) — Legal counsel for the Registrant
• SEC (regulator) — Securities and Exchange Commission
• Delaware (regulator) — State of incorporation
• 202 North California Ave, City of Industry, CA 91744 (company) — Principal executive offices address
• Henry Yin, Esq. (person) — Legal counsel from Loeb & Loeb LLP
• Erik Mengwall, Esq. (person) — Legal counsel from Loeb & Loeb LLP
• Michael Blankenship (person) — Legal counsel from Winston & Strawn LLP

FAQ

Industry Context

The filing of an S-1/A by Papa Medical Inc. suggests an intent to enter the public markets. However, the listed SIC code of 'Cigarettes' [2111] is highly incongruous with the company's name, 'Papa Medical Inc.', raising immediate questions about its actual business operations and industry positioning. This discrepancy warrants further investigation into the company's core business activities and market segment.

Regulatory Implications

The unusual SIC code assignment for Papa Medical Inc. could attract scrutiny from regulatory bodies and investors alike. Companies are expected to accurately represent their business activities, and a significant mismatch like this may necessitate clarification or correction in future filings to ensure compliance and transparency.

What Investors Should Do

1. Investigate the discrepancy between the company name 'Papa Medical Inc.' and its listed SIC Code '2111 (Cigarettes)'.
2. Review future filings for detailed financial statements and business descriptions.
3. Monitor the appointment and background of Hua Yao as Chief Financial Officer.

Key Dates

• 2025-08-07: Filing of S-1/A Amendment No. 3 — Indicates the company is moving forward with its public offering process, with the sale expected as soon as practicable.

Glossary

S-1/A

An amendment to an S-1 registration statement filed with the SEC. It's used to update or correct information before the initial public offering (IPO). (This is the core document detailing Papa Medical Inc.'s intent to go public and the procedural steps involved.)

SIC Code

Standard Industrial Classification code, a four-digit number used by the U.S. government to classify industries. (The SIC code '2111' (Cigarettes) is listed for Papa Medical Inc., which is highly unusual and potentially misleading for a company identified as 'Medical'.)

CIK

Central Index Key, a unique identifier assigned to each entity that files with the SEC. (Provides a definitive way to track Papa Medical Inc.'s filings and history with the SEC.)

Fiscal Year End

The last day of a company's accounting year. (Indicates that Papa Medical Inc.'s financial reporting cycle concludes on December 31st each year.)

Agent for Service

A designated individual or entity responsible for receiving legal documents on behalf of a company. (Hua Yao has been appointed as the agent for service, a standard requirement for public companies, especially those incorporated in Delaware.)

Year-Over-Year Comparison

As this is Amendment No. 3 to the S-1 registration statement, and the initial analysis indicates that specific financial figures are not provided in this amendment, a comparison of key metrics like revenue growth or margin changes to a previous year's filing is not possible at this stage. The amendment primarily focuses on administrative updates, including the appointment of a new CFO and agent for service, rather than reporting on operational performance.

Key Financial Figures

• $4 — blic offering price is expected to be US$4 per share. Currently, no public market
• $1.235 — Company As a company with less than US$1.235 billion in revenue for our last

Filing Documents

• ea0207244-09.htm (S-1/A) — 8349KB
• ea020724409ex1-1_papa.htm (EX-1.1) — 284KB
• ea020724409ex5-1_papa.htm (EX-5.1) — 10KB
• ea020724409ex23-1_papa.htm (EX-23.1) — 4KB
• ex5-1_001.jpg (GRAPHIC) — 2KB
• tcannapresso_logo.jpg (GRAPHIC) — 60KB
• tustigersecurities.jpg (GRAPHIC) — 41KB
• tbarchart_001.jpg (GRAPHIC) — 309KB
• tbarchart_002.jpg (GRAPHIC) — 333KB
• timage_001.jpg (GRAPHIC) — 274KB
• tbarchart_003.jpg (GRAPHIC) — 230KB
• tbarchart_004.jpg (GRAPHIC) — 179KB
• tflowchart_001.jpg (GRAPHIC) — 169KB
• timage_007.jpg (GRAPHIC) — 82KB
• timage_005.jpg (GRAPHIC) — 67KB
• timage_011.jpg (GRAPHIC) — 124KB
• timage_012.jpg (GRAPHIC) — 57KB
• timage_002.jpg (GRAPHIC) — 12KB
• timage_010.jpg (GRAPHIC) — 127KB
• ex23-1_001.jpg (GRAPHIC) — 15KB
• ex23-1_002.jpg (GRAPHIC) — 9KB
• 0001213900-25-072819.txt ( ) — 11528KB

Underwriting

Underwriting Discounts and Commissions (1)   Proceeds, before Expenses, to us Per Share   US$ 4   US$ 0.28   US$ 3.72 Total   US$ 5,000,000   US$ 350,000   US$ 4,650,000 Total With Exercise of Over-Allotment Option   US$ 5,750,000   US$ 402,500   US$ 5,347,500 ____________ (1)        For a description of compensation payable to the underwriters, see “Underwriting.” The underwriters have an option to purchase up to 187,500 additional Class A common stock from us at the initial public offering price, less the underwriting discounts and commissions, within 45 days from the date of this prospectus, to cover any over -allotment . The underwriters expect to deliver the Class A common stock against payment in U.S. dollars in New York, NY to purchasers on or about [          ], 2025. Prospectus dated [      ], 2025   Table of Contents TABLE OF CONTENTS   Page Prospectus Summary   1 The Offering   6

Risk Factors

Risk Factors   8 Special Note regarding Forward-Looking Statements and Industry Data   30

Use of Proceeds

Use of Proceeds   32 Dividend Policy   33 Capitalization   34

Dilution

Dilution   35 Enforceability of Civil Liabilities   36 Selected Consolidated Financial Data   37 Management’s Discussion and Analysis of Financial Condition and Results of Operations   40 Industry Overview   53

Business

Business   61 Regulation   70 Management   76

Executive Compensation

Executive Compensation   80 Principal Stockholders   82 Certain Relationships and Related Party Transactions   83

Description of Capital Stock

Description of Capital Stock   86 Shares Eligible For Future Sale   88 Material U.S. Federal Income Considerations to Non-U . s . Holders   89

Underwriting

Underwriting   92 Legal Matters   99 Experts   99 Where You Can Find Additional Information   99 Index to Consolidated Financial Statements   F-1 Exhibit Index   II-4

Signatures

Signatures   II-5 This prospectus contains certain estimates and information concerning our industry, including market position, market size, and growth rates of the markets in which we participate. This information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to these estimates. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the “Risk Factors” section. These and other factors could cause results to differ materially from those expressed in these publications and reports. You should rely only on the information contained in this prospectus or in any related free -writing prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus or in any related free -writing prospectus. We are offering to sell, and seeking offers to buy, the Class A common stock offered hereby, but only under circumstances and in jurisdictions where offers and sales are permitted and lawful to do so. The information contained in this prospectus is current only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of the Class A common stock. i Table of Contents Neither we nor the underwriters have taken any action that would permit a public offering of the Class A common stock outside the United States or permit the possession or distribution of this prospectus or any filed free -writing prospectus outside the United States. Persons outside the United States who come into possession of this prospectus or any filed free -writing prospectus must inform themselves about and observe any restrictions relating to the offering of the Class A common stock and the distribution of this prospectus or any filed free -writing prospectus outside the United States. Until [  &#x00a

View Full Filing

View this S-1/A filing on SEC EDGAR